VistaGen Therapeutics, Inc.
VTGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | -$0 | $0 |
| % Growth | 5.7% | 1,726.7% | -106.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | 100% | 30.7% | 100% | 100% |
| R&D Expenses | $16 | $12 | $10 | $11 |
| G&A Expenses | $4 | $4 | $4 | $4 |
| SG&A Expenses | $4 | $4 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $20 | $16 | $14 | $15 |
| Operating Income | -$20 | -$16 | -$14 | -$15 |
| % Margin | -7,772.5% | -6,477% | 96,633.3% | -6,461.5% |
| Other Income/Exp. Net | $1 | $1 | $1 | $1 |
| Pre-Tax Income | -$19 | -$15 | -$14 | -$14 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$19 | -$15 | -$14 | -$14 |
| % Margin | -7,526% | -6,186.5% | 90,900% | -6,020.9% |
| EPS | -0.54 | -0.47 | -0.44 | -0.46 |
| % Growth | -14.9% | -6.8% | 4.3% | – |
| EPS Diluted | -0.54 | -0.47 | -0.44 | -0.46 |
| Weighted Avg Shares Out | 36 | 32 | 31 | 31 |
| Weighted Avg Shares Out Dil | 36 | 32 | 31 | 31 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$19 | -$15 | -$14 | -$15 |
| % Margin | -7,454.3% | -6,117.2% | 95,526.7% | -6,392.7% |